Previous research, in rat models of SpA and RA (50, 51), has demonstrated that dual inhibition of TNF and IL17 significantly reduces inflammation and structural damage compared with monotherapy, suggesting a synergic benefit. This evidence concerns the gene IL17A and rheumatoid arthritis.